Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients
Ulrich et al.,
Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in..,
Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa446, TEACH, NCT04369742
Small RCT on very late stage use of HCQ, with 48% on oxygen at baseline. 67 HCQ patients, 61 control. Baseline states were not comparable - 82% more HCQ patients had the highest severity at baseline, there was 32% more male HCQ patients, and 44% more control patients used AZ. The HCQ group also had significantly more patients with cerebrovascular disease, cardiovascular disease (non-hypertension), renal disease (non-dialysis), and a history of organ transplants.
This study is excluded in the after exclusion results of meta
analysis:
very late stage, >50% on oxygen/ventilation at baseline.
risk of death, 6.0% higher, RR 1.06, p = 1.00, treatment 7 of 67 (10.4%), control 6 of 61 (9.8%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ulrich et al., 23 Sep 2020, Randomized Controlled Trial, USA, peer-reviewed, baseline oxygen required 63.3%, mean age 66.2, 18 authors, average treatment delay 7.0 days, trial
NCT04369742 (history) (TEACH).
Abstract: TREATING COVID-19 WITH HYDROXYCHLOROQUINE
(TEACH): A MULTICENTER, DOUBLE-BLIND, RANDOMIZED
CONTROLLED TRIAL IN HOSPITALIZED PATIENTS
Robert J. Ulrich MD1,4,*, Andrea B. Troxel ScD3,7, Ellie Carmody MD, MPH1,4, Jaishvi Eapen
MD1,4, Martin Bäcker MD10, Jack A. DeHovitz MD, MPH, MHCDS, FACP9, Prithiv J. Prasad
Brooklyn Henderson RN1,4, Alexander Hrycko MD1,4, Dinuli Delpachitra MBBS10, Vanessa
Raabe MD1,2,4,6,5, Jonathan S. Austrian MD1, Yanina Dubrovskaya PharmD, BCIDP1,4,11, and
Mark J. Mulligan, MD, FIDSA1,4
1
Department of Medicine, New York University Grossman School of Medicine. New York, NY, USA.
2
Department of Pediatrics, New York University Grossman School of Medicine. New York, NY, USA.
3
Department of Population Health, New York University Grossman School of Medicine. New York, NY, USA.
4
Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine. New York, NY, USA.
5
Divison of Pediatric Infectious Diseases, New York University Grossman School of Medicine. New York, NY, USA.
6
Division of Pediatric Hematology-Oncology, New York University Grossman School of Medicine. New York, NY, USA.
7
Division of Biostatistics, New York University Grossman School of Medicine. New York, NY, USA.
8
New York University Grossman School of Medicine. New York, NY, USA.
9
Department of Medicine, Division of Infectious Diseases, State University of New York Downstate Health Sciences University, Brooklyn, NY,
USA.
10
Department of Medicine, Division of Infectious Diseases, NYU Long Island School of Medicine. Mineola, NY, USA.
11
Department of Pharmacy, NYU Langone Health. New York, NY, USA.
*Corresponding Author: Robert J. Ulrich MD. 551 First Ave, New York NY 10016, United
States. Email: robert.ulrich@nyulangone.org
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society
of America.
This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which
permits non-commercial reproduction and distribution of the work, in any medium, provided the
original work is not altered or transformed in any way, and that the work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com
MBBS1,4, Yi Li MS3,7, Camila Delgado PhD8, Morris Jrada MD1, Gabriel A. Robbins MD2,6,
Author Contributions: RJU, ABT, EC, VR and MJM contributed to the concept, design and
protocol development. RJU, EC, JE, MB, JAD and PJP contributed as site leaders
overseeing all trial operations and data quality from each site. MJ, GAR, BH, AH, DD and YD
contributed to trial operations and data entry. RJU, ABT, CD, and YL contributed to data
analysis. JSA created novel information technology for trial operations. RJU and ABT drafted
the manuscript. All authors provided critical revisions and approved the final manuscript.
Clinicaltrials.gov # NCT04369742
2
Abstract
Background:
Effective therapies to combat COVID-19 are urgently needed. Hydroxychloroquine
(HCQ) has in vitro..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit